Biotechnology·Intelligence·Impact
Therapeutics designed from first principles.
A physics-grounded platform for the design and optimization of antibodies and small molecules — built for decision-quality science.
A physics-grounded platform for the design and optimization of antibodies and small molecules — built for decision-quality science.
ab initium is a physician-led biotechnology company. Our platform is built on a patent-protected mathematical and logical framework that treats molecular design as transparent, reproducible methods — not as black-box pattern matching.
Every candidate we produce is computed from physics and scored against the same first principles — fully traceable, end to end. We work across modalities, from de novo design to refinement of existing leads, in partnership with pharmaceutical and biotech sponsors.
Heavy-chain framework (blue) and light-chain framework (green) cradle the combining site. Contact residues identified by the platform crowd the small-molecule pose at center — generated, ranked, and audited within a single deterministic pipeline.
Generate new antibody and small-molecule candidates against defined targets, grounded in mechanistic physics rather than learned correlations.
Refine existing leads for affinity, selectivity, developability, and manufacturability with transparent, reproducible trade-offs.
Physics-grounded scoring with auditable provenance, gating candidates on safety, specificity, and reproducibility before resources commit.
Engagements typically begin with a confidential scoping conversation. We respond to qualified inquiries within two business days.
Contact us →